Sort by
Refine Your Search
-
Listed
-
Country
-
Employer
- University of Washington
- Yale University
- Umeå University
- Stanford University
- University of Minnesota
- University of North Carolina at Chapel Hill
- Cornell University
- Nencki Institute of Experimental Biology
- St Jude Children's Research Hospital
- University of Maryland, Baltimore
- Baylor College of Medicine
- Karolinska Institutet (KI)
- King's College London
- Northeastern University
- Rutgers University
- The University of Arizona
- University of California, Los Angeles
- CeMM - Research Center for Molecular Medicine of the Austrian Academy of Sciences
- FAPESP - São Paulo Research Foundation
- Fondazione per l'Istituto oncologico di ricerca IOR
- German Cancer Research Center in the Helmholtz Association (DKFZ)
- Harvard University
- Heidelberg University
- Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt
- INSERM
- Institut d'Investigació Biomèdica Sant Pau
- Josep Carreras Leukaemia Research Institute (IJC)
- KU LEUVEN
- Lunds universitet
- Medizinische Universitaet Wien
- Michigan State University
- New York University
- Oak Ridge National Laboratory
- Research Center for Molecular Medicine (CeMM), ÖAW
- The International Institute of Molecular Mechanisms and Machines Polish Academy of Sciences
- The University of North Carolina at Chapel Hill
- The University of Texas at Dallas
- UNIVERSITY OF HELSINKI
- UNIVERSITY OF VIENNA
- University College Dublin
- University Medical Center Utrecht (UMC Utrecht)
- University of Colorado
- University of Copenhagen
- University of Illinois Chicago
- University of Michigan - Ann Arbor
- University of Texas at Dallas
- Université de Reims Champagne Ardenne
- VIB
- Washington University in St. Louis
- Yale University - Department of Genetics
- 40 more »
- « less
-
Field
-
proliferative). • Investigate how ECM composition and mechanical properties regulate melanoma cell states and behaviour using CRISPR-Cas9-mediated perturbations, advanced imaging approaches, and physiologically
-
already in place: Existing genome-wide CRISPR screening data from RLT and EBRT models, with compelling hits already identified and a clear path towards clinical translation Isogenic radio-resistant and
-
-erythrocytic and transmission stages of the parasite lifecycle. Current projects include CRISPR/Cas9-based parasite engineering, functional characterization of parasite genes involved in liver infection and
-
-leading research in several fields. Notably, the groundbreaking discovery of the CRISPR-Cas9 gene-editing tool, which was awarded the Nobel Prize in Chemistry, was made here. At Umeå University, everything
-
level, experience in isolating and working with primary immune cells, experience in precise genetic engineering, for example using CRISPR/Cas9. Further information The position is a full-time fixed-term
-
disease (IBD), and/or experimental autoimmune encephalomyelitis (EAE). Using unbiased genome-wide CRISPR/Cas9 guide RNA library screens and whole kinome analyses, we have identified promising novel
-
CeMM - Research Center for Molecular Medicine of the Austrian Academy of Sciences | Austria | 2 months ago
CRISPR screening (Bock 2022 Nature Reviews ), and CAR T cell engineering (... Where to apply Website https://www.eurosciencejobs.com/job_display/293955/CeMM_International_Postdoc_P… Requirements Additional
-
thromboinflammation, using cutting-edge approaches such as confocal intravital microscopy, CRISPR-based gene editing, proteomics, and mouse models of human disease. Job Description Primary Duties & Responsibilities
-
Postdoctoral Associate | Mitochondrial Genomics | Lake Lab — Yale University, Department of Genetics
our research please see our website: https://www.thelakelab.org/ Responsibilities Generate and characterize novel cellular models of mitochondrial genome dysfunction using genome-editing and related
-
and lignocellulosic biomass into domestic fuels and chemicals. Research activities may include creating transformation methods, constructing gene‑expression “genetic parts,” and developing CRISPR‑Cas